Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing, “The Need to Make Insulin Affordable for All Americans,”
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the Energy and Commerce Subcommittee on Oversight and Investigations for holding today’s hearing on the important issue of rising insulin prices. “Drugmakers are solely responsible for setting and raising prescription
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s vote in the Energy and Commerce Subcommittee on Health on the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act:
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. Pandemic Vaccine: Safety Top Priority for Rx Supply Chain… As states
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting pharmacy benefits would increase health care costs at a time when premiums continue to rise
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the Senate Judiciary Committee’s vote to pass, S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act: “Today’s vote in the
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from the IQVIA Institute that shows net prescription spending is decreasing in settings in which pharmacy benefit management (PBM) tools are widely used.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on today’s remarks by Food and Drug Administration Commissioner Scott Gottlieb, specifically those appearing to reference drug manufacturer abuses of risk evaluation and mitigation strategies (REMS) that
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International Convention happening this week in Boston, MA misses the critical opportunity to address the root
©2024 PCMA. All Rights Reserved.
